NCT03485729 - ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

January 19, 2023

Study Completion Date

January 19, 2023

Conditions

Endometrial Cancer Recurrent

Interventions

DRUG

Dordaviprone (ONC201)

625 mg dordaviprone (ONC201)

Trial Locations (3)

Fox Chase Cancer Center, Philadelphia

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Rutgers, The State University of New Jersey, New Brunswick